Skip to main content

Charles B. Simone, MD

Academic Title:

Associate Professor

Primary Appointment:

Radiation Oncology

Administrative Title:

Medical Director, Maryland Proton Therapy Center

Education and Training

Aug 2002 – May 2006
MD, University of Pennsylvania School of Medicine

June 2006 – June 2007
Internship, Department of Medicine, Graduate Hospital, Philadelphia, PA

July 2007 – June 2011
Residency, Radiation Oncology Branch, National Capital Consortium (NCC), National Cancer Institute (NCI), National Institutes of Health (NIH)

July 2010 – June 2011
Chief Resident, Radiation Oncology, NCC, National Cancer Institute, NIH

Biosketch

 

Dr. Charles B. Simone, II is the Medical Director of the Maryland Proton Treatment Center, an Associate Professor of Radiation Oncology at the University of Maryland School of Medicine, and the Fellowship Director for the Department of Radiation Oncology.  He is an internationally recognized expert in the use of proton therapy to treat thoracic malignancies and for reirradiation, and in the development of clinical trial strategies and innovative research in thoracic radiation oncology and stereotactic body radiation therapy.

 

He completed his undergraduate and medical school training at the University of Pennsylvania. He completed an internship in internal medicine, and then he completed residency training in radiation oncology at the National Cancer Institute, National Institutes of Health, where he served as chief resident.  Prior to his appointment at University of Maryland, Dr. Simone was an Associate Professor of Radiation Oncology, Chief of the Thoracic Oncology Service at the Hospital of the University of Pennsylvania, Co-Director of the Penn Mesothelioma and Pleural Program for the University of Pennsylvania Health System, and Director of Clinical Research and Operations for the Department of Radiation Oncology at Penn.

 

Dr. Simone uses proton and photon radiation therapy to treat patients with lung cancer, malignant pleural mesothelioma, thymic malignancies, and other thoracic malignancies, as well as recurrent malignancies and sarcomas.  He is a National Institutes of Health, National Science Foundation, and Department of Defense funded investigator who performs clinical and translational research investigating the benefits of proton therapy as part of multi-modality therapy for thoracic malignancies.  He has published >150 peer-reviewed scientific articles and book chapters and given >100 scientific lectures to national and international audiences. 

 

He is the Chair of the Proton Collaborative Group (PCG) Executive Committee, Chair of the PCG Lung Committee, and Chair of the American Society for Photobiology (ASP) Education Committee. He is appointed to the NRG Oncology (formerly Radiation Therapy Oncology Group [RTOG]) Lung Cancer Core Committee; NRG Radiation Oncology Committee; NCI Thoracic Malignancies Steering Committee Mesothelioma Working Group; International Thymic Malignancy Interest Group (ITMIG) Research and Infrastructure Committee; ITMIG Thymic Carcinoma Workgroup; American Society for Radiation Oncology (ASTRO) Lung Cancer “Blue Ribbon” Panel; ASP Executive Council; PCG Reirradiation Committee; Particle Therapy Co-Operative Group (PTCOG) Scientific Committee; and multiple PTCOG Clinical Subcommittees.

 

 

 

 

 

 

Research/Clinical Keywords

lung cancer, mesothelioma and thoracic malignancies